Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 13, 2021 09:05 ET | Source: Affimed N.V.

Affimed Shares Preclinical Data on Innate Cell Engagers AFM28 and AFM13 at the 63rd American Society of Hematology Annual Meeting and Exposition

AFM28 effectively induces depletion of leukemic cells in patient bone marrow samples and demonstrates the anticipated good safety profile and pharmacologic activity in cynomolgus monkeysPre-complexing...
December 09, 2021 06:30 ET | Source: Affimed N.V.

Affimed to Host Virtual Investor Call Today to Discuss Treatment of CD30-positive Lymphoma Patients with Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13

For the 13 patients treated at the recommended phase 2 dose (RP2D) the response rate after one cycle of treatment remains at 100% with a 38.5% complete response (CR) rate; one additional patient...
December 08, 2021 06:30 ET | Source: Affimed N.V.

Affimed Initiates Patient Recruitment for a Phase 1/2a Trial of Innate Cell Engager AFM24 in Combination with Roche’s Anti-PD-L1 Checkpoint Inhibitor Atezolizumab

HEIDELBERG, Germany, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...
November 22, 2021 07:11 ET | Source: Affimed N.V.

Affimed Announces 100% Objective Response Rate at Highest Dose in Phase 1-2 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13 for CD30-positive Lymphomas

100% objective response rate with a 42% complete response rate in 12 patients, according to investigator assessment, after the 1st of 2 planned cycles at the recommended phase 2 dose of 108 cord...
November 12, 2021 07:01 ET | Source: Affimed N.V.

Affimed Shares Preclinical Data on Mechanism of Action of two Innate Cell Engagers at the 36th SITC Meeting, Demonstrating their Potential to Induce Antibody Dependent Cellular Phagocytosis and Serial Killing

HEIDELBERG, Germany, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...
November 10, 2021 06:30 ET | Source: Affimed N.V.

Affimed Reports Third Quarter 2021 Financial Results and Highlights Operational Progress

AFM13 monotherapy: Enrollment is on track and expected to be completed in the first half of 2022.AFM13 combination with NK cells: Updated data to be presented at company-sponsored event in...
November 09, 2021 06:30 ET | Source: Affimed N.V.

Affimed to Present at Upcoming Investor Conferences

HEIDELBERG, Germany, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...
November 08, 2021 06:30 ET | Source: Affimed N.V.

Affimed and NKGen Biotech Announce Initiation of Patient Recruitment in a First-in-human Phase 1/2a Trial of Innate Cell Engager AFM24 in Combination with Autologous NK Cell Product SNK01

Patient recruitment is open for the first-in-human proof of concept trial of the combination of AFM24 and SNK01 NK cells in three advanced or metastatic EGFR-expressing cancers, namely non-small cell...
November 04, 2021 09:06 ET | Source: Affimed N.V.

Affimed Announces New Innate Cell Engager AFM28 Targeting CD123 to Treat Acute Myeloid Leukemia

Derived from Affimed’s ROCK® platform, AFM28 binds selectively and with high affinity the surface antigens CD123 and CD16AAFM28 shows better killing of primary leukemic blasts in comparison to...
November 04, 2021 09:05 ET | Source: Affimed N.V.

Affimed Announces Poster Presentations at the 63rd American Society of Hematology Annual Meeting and Exposition and Company-sponsored Event on AFM13

A poster presentation featuring preclinical data on AFM28, a novel Innate Cell Engager developed for treatment of Acute Myeloid Leukemia and other CD123+ myeloid malignanciesA poster presentation on...